Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Titre original de l'avis
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Score d'opportunité
Pourquoi ce score ?
Opportunité
60 / 100
Complexité
20 / 100
Facteurs de risque
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Informations clés
- Pouvoir adjudicateur
- Techniker Krankenkasse
- Pays
- Allemagne
- CPV
- 33600000 - Pharmaceutical products
- Date limite
- Feb 27, 2027
Aperçu
Strong opportunityFaits clés
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Pharmaceutical discount contract for Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
- Supply of the drug under uniform conditions set by TK
Afficher le résumé complet
Open House procedure by Techniker Krankenkasse (TK) for discount contracts on the drug Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) under §130c SGB V. The procedure allows continuous joining during the contract term (max 24 months from March 2025 to February 2027). No estimated value provided; no competition or award criteria; eligibility requires being a pharmaceutical entrepreneur with authorization for the drug. Submission is by email (with qualified electronic signature) or post. Documents are available but were not analyzed.
Risques
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
- Must have a valid marketing authorization for the drug in Germany or be otherwise entitled to market it
Eligibility
- Must provide a self-declaration confirming eligibility and no exclusion grounds
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
Hamburg, DEU
Site web
Identifiant
992-80116-93
Activité
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
Discount contracts for the combination drug Bictegravir/Emtricitabin/Tenofoviralafenamid. Continuous enrollment; no exclusivity; standard conditions.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) zu schließen.
Note sur la valeur
Afficher les données TED originales
Description TED originale
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130c Abs. 1 SGB V zur Wirkstoffkombination Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) zu schließen.
Détails de la procédure
- Date de publication
- 19 Jan 2025
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 39458-2025
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
60 / 100
Complexité
20 / 100
Facteurs de risque
The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...
Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications